Table 8.
Pharmacokinetic parameters of cannabidiol and metabolites for the food effect arm of the trial
| Pharmacokinetic parameter (unit) | 1500 mg CBD, fasted (n = 12) | 1500 mg CBD, fed (n = 12) |
|---|---|---|
| CBD | ||
| Cmax (ng/mL)a | 335.4 (81.3) | 1628 (51.4) |
| AUCt (ng·h/mL)a | 1987 (53.6) | 8347 (34.1) |
| AUC∞ (ng·h/mL)a | 2198 (48.2) | 8669 (33.9) |
| tmax (h)b | 3.50 (2.50–5.03) | 3.00 (1.50–5.00) |
| t½,z (h)c | 30.33 (28.5) | 24.40 (16.0) |
| CL/F (L/h)c | 751.8 (46.6) | 182.0 (34.2) |
| Vz/F (L/h)c | 34,101 (60.5) | 6349 (31.6) |
| 6-OH-CBD | ||
| Cmax (ng/mL)a | 9.6 (47.7) | 26.8 (47.0) |
| AUCt (ng·h/mL)a | 96.93 (44.0) | 255.6 (40.2) |
| AUC∞ (ng·h/mL)a | 113.3 (34.0)d | 279.1 (39.7) |
| tmax (h)b | 2.50 (1.00–5.00) | 3.00 (0.50–5.00) |
| t½,z (h)c | 20.31 (30.4)d | 22.80 (53.3) |
| 7-OH-CBD | ||
| Cmax (ng/mL)a | 135.2 (54.7) | 393.1 (35.8) |
| AUCt (ng·h/mL)a | 1065 (43.2) | 3365 (32.7) |
| AUC∞ (ng·h/mL)a | 1051 (37.0)e | 3467 (32.5) |
| tmax (h)b | 2.75 (1.50–5.03) | 3.00 (1.50–5.00) |
| t½,z (h)c | 18.74 (18.7)e | 15.88 (17.8) |
| 7-COOH-CBD | ||
| Cmax (ng/mL)a | 2426 (61.0) | 5044 (33.8) |
| AUCt (ng·h/mL)a | 56,865 (56.6) | 137,421 (32.9) |
| AUC∞ (ng·h/mL)a | 65,496 (54.2) | 154,160 (34.1) |
| tmax (h)b | 4.00 (3.00–5.03) | 5.00 (3.00–6.02) |
| t½,z (h)c | 23.51 (26.0) | 21.20 (20.9) |
AUCt area under the plasma concentration-time curve from time zero to time t, AUC∞ area under the concentration-time curve from time zero to infinity, 7-COOH-CBD 7-carboxy-cannabidiol, 6-OH-CBD 6-hydroxy-cannabidiol, 7-OH-CBD 7-hydroxy-cannabidiol, CBD cannabidiol, CL/F oral clearance of drug from plasma, Cmax maximum measured plasma concentration, CV% percentage coefficient of variation, tmax time to maximum plasma concentration, t½,z terminal elimination half-life, Vz/F apparent volume of distribution
aGeometric mean (geometric CV%)
bMedian (range)
cArithmetic mean (arithmetic CV%)
dn = 10
en = 11